| Literature DB >> 32831825 |
Yasutoshi Shiratori1, Takashi Ikeya1, Kenji Nakamura2, Katsuyuki Fukuda1.
Abstract
METHODS: We used alginade water (125 mL, Nestle Co., Kobe, Japan) for PORT. Alginade water is a flavored sports drink, which is palatable and promotes wound healing due to a high concentration of alginate. We conducted a single-center single-arm prospective feasibility study of PORT in 244 patients who underwent upper gastrointestinal ESD. The group wherein PORT was administered up to two hours before ESD (n = 120) was compared with the historical control group (non-PORT group, n = 120). We investigated the total fluid intake, hematocrit change, complications due to PORT, complications during ESD, ESD procedure time, and length of hospital stay in each group.Entities:
Year: 2020 PMID: 32831825 PMCID: PMC7428898 DOI: 10.1155/2020/4372503
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Study flow diagram showing the selection of cases. For a total of 244 patients, upper gastrointestinal endoscopic submucosal dissection was performed in a tertiary hospital in Tokyo, Japan. Of these, 240 patients were included in this study. The patients were classified into the PORT and non-PORT groups. PORT: per oral rehydration therapy.
Composition of the oral rehydration solution.
| Alginate water (per pack) | |
|---|---|
| Volume (mL) | 125 |
| Energy (kcal) | 100 |
| Carbohydrate (g) | 22.5 |
| Protein (g) | 5 (alginic acid 2.5) |
| Sodium (mg) | 0 |
| Potassium (mg) | 400 |
| Vitamin A ( | 150 |
| Vitamin C (mg) | 500 |
| Vitamin E (mg) | 5 |
| Zinc (mg) | 10 |
| Iron (mg) | 0 |
Figure 2Time course for the PORT group and non-PORT group. In the PORT group, 500 mL of alginade water was administered up to 2 hours before ESD. In contrast, 500 mL of extracellular fluid infusion was administered in the non-PORT group before ESD. ESD: endoscopic submucosal dissection; PORT: preoperative oral rehydration therapy.
Patient characteristics.
| PORT (120) | Non-PORT (120) |
| |
|---|---|---|---|
| Age (mean ± SD) | 70.6 ± 11.7 | 71.9 ± 10.4 | 0.47 |
| Sex (male, female) | 93, 27 | 90, 30 | 0.71 |
| Hematocrit before admission (mean ± SD, %) | 36.9 ± 3.7 | 37.4 ± 3.8 | 0.85 |
| Comorbidity for Charlson's score (mean ± SD) | 1.0 ± 1.7 | 1.1 ± 1.5 | 0.57 |
| Myocardial infarction | 5 | 6 | 0.76 |
| Cerebral infarction | 3 | 3 | 1 |
| Diabetic mellitus | 10 | 12 | 0.66 |
| Chronic kidney disease | 4 | 5 | 0.73 |
| Antithrombotic therapy | 8 | 10 | 0.62 |
| Location (esophagus, stomach, and duodenum) | 39, 79, 2 | 44, 76, 0 | 0.48 |
PORT: preoperative oral rehydration therapy; SD: standard deviation.
Outcomes of the PORT group and non-PORT group.
| PORT | Non-PORT | P-value | |
|---|---|---|---|
| Total intake (mean ± SD, mL) | 462.6 ± 29.2 | 0 | N/A |
| Volume infusion | 0 | 500 | N/A |
| Complications due to PORT | 0 | N/A | N/A |
| Complications during ESD | 0 | 0 | N/A |
| Hematocrit change (mean ± SD, %) | 1.3 ± 1.7 | 1.4 ± 1.4 | 0.75 (95% CI: -0.5, 0.3) |
| Procedure time (mean ± SD, min) | 73.2 ± 4.8 | 77.9 ± 4.9 | 0.72 (95% CI: -15.8, 22.8) |
| Hospitalization days (mean ± SD) | 5.2 ± 0.1 | 5.2 ± 0.1 | 0.93 (95% CI: -0.16, 0.18) |
CI: confidence interval; ESD: endoscopic submucosal dissection; N/A: not applicable PORT: preoperative oral rehydration therapy; SD: standard deviation.